Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatectomy | 39 | 2022 | 60 | 10.430 |
Why?
|
| Liver Neoplasms | 31 | 2022 | 102 | 9.380 |
Why?
|
| Portal Vein | 30 | 2022 | 45 | 8.340 |
Why?
|
| Liver | 21 | 2022 | 142 | 6.580 |
Why?
|
| Liver Regeneration | 17 | 2022 | 24 | 4.810 |
Why?
|
| Colorectal Neoplasms | 13 | 2021 | 109 | 3.300 |
Why?
|
| Ligation | 22 | 2022 | 37 | 2.410 |
Why?
|
| Embolization, Therapeutic | 6 | 2021 | 54 | 2.200 |
Why?
|
| Laparoscopy | 6 | 2021 | 143 | 1.660 |
Why?
|
| Hepatic Stellate Cells | 2 | 2020 | 3 | 1.260 |
Why?
|
| Postoperative Complications | 13 | 2022 | 864 | 1.250 |
Why?
|
| Liver Diseases | 2 | 2018 | 31 | 1.090 |
Why?
|
| Cause of Death | 3 | 2017 | 56 | 1.030 |
Why?
|
| Registries | 9 | 2019 | 176 | 1.010 |
Why?
|
| Humans | 56 | 2024 | 24703 | 0.990 |
Why?
|
| Liver Failure | 4 | 2019 | 10 | 0.910 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2021 | 25 | 0.870 |
Why?
|
| Treatment Outcome | 20 | 2021 | 3208 | 0.850 |
Why?
|
| Hypoxia | 2 | 2020 | 27 | 0.790 |
Why?
|
| Hypertrophy | 5 | 2022 | 22 | 0.780 |
Why?
|
| Male | 36 | 2021 | 13669 | 0.740 |
Why?
|
| Organ Size | 9 | 2019 | 93 | 0.730 |
Why?
|
| Retrospective Studies | 17 | 2022 | 3156 | 0.710 |
Why?
|
| Sarcopenia | 1 | 2021 | 29 | 0.700 |
Why?
|
| Neovascularization, Pathologic | 1 | 2020 | 29 | 0.660 |
Why?
|
| Kidney Transplantation | 5 | 2021 | 98 | 0.650 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 67 | 0.650 |
Why?
|
| Middle Aged | 26 | 2019 | 8294 | 0.640 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 11 | 0.610 |
Why?
|
| Female | 31 | 2021 | 14048 | 0.610 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 244 | 0.600 |
Why?
|
| Hepatomegaly | 1 | 2018 | 7 | 0.600 |
Why?
|
| Reperfusion Injury | 1 | 2018 | 2 | 0.600 |
Why?
|
| Neuroendocrine Tumors | 5 | 2019 | 50 | 0.600 |
Why?
|
| Publication Bias | 1 | 2018 | 4 | 0.590 |
Why?
|
| Antioxidants | 1 | 2018 | 60 | 0.580 |
Why?
|
| Oxidative Stress | 1 | 2018 | 94 | 0.580 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 107 | 0.580 |
Why?
|
| Bibliometrics | 1 | 2018 | 26 | 0.570 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 21 | 0.550 |
Why?
|
| Aged | 20 | 2019 | 8382 | 0.530 |
Why?
|
| Length of Stay | 5 | 2021 | 294 | 0.520 |
Why?
|
| Pancreatic Neoplasms | 4 | 2024 | 86 | 0.510 |
Why?
|
| Therapies, Investigational | 1 | 2016 | 5 | 0.500 |
Why?
|
| Animals | 8 | 2021 | 3330 | 0.490 |
Why?
|
| Catheter Ablation | 1 | 2015 | 45 | 0.450 |
Why?
|
| Graft Rejection | 4 | 2008 | 60 | 0.440 |
Why?
|
| Liver Transplantation | 3 | 2015 | 85 | 0.430 |
Why?
|
| Prognosis | 8 | 2020 | 674 | 0.410 |
Why?
|
| Time Factors | 9 | 2019 | 1327 | 0.410 |
Why?
|
| Risk Factors | 10 | 2019 | 2099 | 0.410 |
Why?
|
| Hepatic Veins | 4 | 2022 | 9 | 0.410 |
Why?
|
| Blood Loss, Surgical | 3 | 2019 | 53 | 0.400 |
Why?
|
| Feasibility Studies | 4 | 2016 | 196 | 0.370 |
Why?
|
| Survival Rate | 6 | 2018 | 285 | 0.350 |
Why?
|
| Operative Time | 4 | 2019 | 77 | 0.340 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 1671 | 0.340 |
Why?
|
| Adenocarcinoma | 2 | 2024 | 134 | 0.330 |
Why?
|
| Models, Animal | 3 | 2020 | 108 | 0.320 |
Why?
|
| Tissue Donors | 2 | 2021 | 71 | 0.320 |
Why?
|
| Neoplasm Staging | 5 | 2018 | 332 | 0.320 |
Why?
|
| Random Allocation | 3 | 2018 | 121 | 0.310 |
Why?
|
| Isoantibodies | 2 | 2006 | 7 | 0.310 |
Why?
|
| Intestinal Neoplasms | 2 | 2018 | 12 | 0.300 |
Why?
|
| Adult | 15 | 2019 | 7255 | 0.290 |
Why?
|
| Stomach Neoplasms | 2 | 2018 | 29 | 0.290 |
Why?
|
| Antibodies, Neoplasm | 1 | 2008 | 12 | 0.290 |
Why?
|
| Swine | 2 | 2018 | 63 | 0.290 |
Why?
|
| Pancreas Transplantation | 2 | 2021 | 17 | 0.280 |
Why?
|
| Death | 1 | 2008 | 41 | 0.280 |
Why?
|
| Vascular Surgical Procedures | 2 | 2019 | 18 | 0.280 |
Why?
|
| Patient Selection | 4 | 2018 | 177 | 0.270 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 160 | 0.270 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 104 | 0.270 |
Why?
|
| Rats, Wistar | 2 | 2017 | 44 | 0.270 |
Why?
|
| Rats | 2 | 2020 | 609 | 0.260 |
Why?
|
| Risk Assessment | 5 | 2019 | 532 | 0.260 |
Why?
|
| Switzerland | 3 | 2021 | 7 | 0.260 |
Why?
|
| Plasmapheresis | 1 | 2006 | 11 | 0.250 |
Why?
|
| HLA Antigens | 1 | 2006 | 12 | 0.250 |
Why?
|
| Antibody Formation | 1 | 2006 | 15 | 0.250 |
Why?
|
| Philosophy, Medical | 1 | 2004 | 3 | 0.230 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2024 | 5 | 0.220 |
Why?
|
| Spirituality | 1 | 2004 | 77 | 0.210 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 814 | 0.200 |
Why?
|
| Tissue and Organ Procurement | 3 | 2012 | 33 | 0.190 |
Why?
|
| Ultrasonography | 3 | 2021 | 202 | 0.190 |
Why?
|
| Multivariate Analysis | 4 | 2019 | 304 | 0.190 |
Why?
|
| Cell Proliferation | 2 | 2020 | 167 | 0.190 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 157 | 0.190 |
Why?
|
| Databases, Factual | 3 | 2019 | 315 | 0.190 |
Why?
|
| Biomarkers | 3 | 2020 | 520 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 13 | 0.180 |
Why?
|
| Organ Transplantation | 1 | 2021 | 32 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 20 | 0.180 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 31 | 0.180 |
Why?
|
| Hospitals | 1 | 2021 | 149 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 108 | 0.170 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2020 | 1 | 0.170 |
Why?
|
| Adrenalectomy | 1 | 2019 | 5 | 0.160 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 61 | 0.160 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 62 | 0.160 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2019 | 14 | 0.160 |
Why?
|
| Brazil | 2 | 2016 | 39 | 0.160 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2019 | 15 | 0.160 |
Why?
|
| Hospital Mortality | 3 | 2015 | 121 | 0.160 |
Why?
|
| Parenchymal Tissue | 1 | 2019 | 2 | 0.150 |
Why?
|
| Conversion to Open Surgery | 1 | 2019 | 3 | 0.150 |
Why?
|
| Abdominal Neoplasms | 1 | 2019 | 14 | 0.150 |
Why?
|
| Liver Function Tests | 4 | 2017 | 21 | 0.150 |
Why?
|
| Preoperative Period | 1 | 2019 | 75 | 0.150 |
Why?
|
| Gallium Radioisotopes | 1 | 2018 | 4 | 0.150 |
Why?
|
| Paracrine Communication | 1 | 2018 | 4 | 0.150 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2018 | 11 | 0.150 |
Why?
|
| Culture Media, Conditioned | 1 | 2018 | 19 | 0.150 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 17 | 0.150 |
Why?
|
| Cytoprotection | 1 | 2018 | 9 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 17 | 0.150 |
Why?
|
| Hepatocytes | 1 | 2018 | 10 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 613 | 0.150 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 22 | 0.150 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 31 | 0.150 |
Why?
|
| Anesthesia | 1 | 2018 | 28 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 41 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 35 | 0.150 |
Why?
|
| Models, Biological | 1 | 2020 | 284 | 0.150 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 51 | 0.140 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 44 | 0.140 |
Why?
|
| Logistic Models | 3 | 2016 | 365 | 0.140 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 228 | 0.140 |
Why?
|
| Survival Analysis | 2 | 2017 | 231 | 0.140 |
Why?
|
| Gastric Bypass | 1 | 2018 | 68 | 0.140 |
Why?
|
| Apoptosis | 1 | 2018 | 197 | 0.140 |
Why?
|
| Portal Pressure | 1 | 2017 | 4 | 0.140 |
Why?
|
| Liver Circulation | 1 | 2017 | 5 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 250 | 0.140 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 598 | 0.140 |
Why?
|
| Melanoma | 1 | 2017 | 46 | 0.130 |
Why?
|
| Fatty Liver | 1 | 2017 | 26 | 0.130 |
Why?
|
| Hyperplasia | 1 | 2017 | 18 | 0.130 |
Why?
|
| Cell Hypoxia | 1 | 2016 | 9 | 0.130 |
Why?
|
| Signal Transduction | 1 | 2018 | 413 | 0.130 |
Why?
|
| Cholangiocarcinoma | 1 | 2016 | 3 | 0.130 |
Why?
|
| Bile Duct Neoplasms | 1 | 2016 | 4 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 162 | 0.130 |
Why?
|
| Obesity | 1 | 2018 | 280 | 0.120 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 560 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2017 | 1748 | 0.120 |
Why?
|
| Primary Graft Dysfunction | 1 | 2015 | 2 | 0.120 |
Why?
|
| Methyl Ethers | 1 | 2015 | 6 | 0.120 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 16 | 0.120 |
Why?
|
| Propofol | 1 | 2015 | 8 | 0.120 |
Why?
|
| Anesthetics, Intravenous | 1 | 2015 | 9 | 0.120 |
Why?
|
| Anesthetics, Inhalation | 1 | 2015 | 12 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 99 | 0.120 |
Why?
|
| Safety | 1 | 2014 | 35 | 0.110 |
Why?
|
| Surgeons | 1 | 2016 | 82 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 85 | 0.110 |
Why?
|
| Renal Artery | 1 | 2013 | 4 | 0.100 |
Why?
|
| Viscera | 1 | 2013 | 2 | 0.100 |
Why?
|
| Vascular Patency | 1 | 2013 | 13 | 0.100 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2013 | 14 | 0.100 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2013 | 11 | 0.100 |
Why?
|
| Aneurysm | 1 | 2013 | 9 | 0.100 |
Why?
|
| Endovascular Procedures | 1 | 2013 | 28 | 0.100 |
Why?
|
| Stents | 1 | 2013 | 62 | 0.100 |
Why?
|
| Blood Transfusion | 1 | 2012 | 61 | 0.100 |
Why?
|
| Linear Models | 1 | 2012 | 234 | 0.090 |
Why?
|
| Bilirubin | 2 | 2016 | 11 | 0.090 |
Why?
|
| Resource Allocation | 1 | 2011 | 4 | 0.090 |
Why?
|
| Health Care Rationing | 1 | 2011 | 5 | 0.090 |
Why?
|
| End Stage Liver Disease | 1 | 2011 | 9 | 0.090 |
Why?
|
| Liver Cirrhosis | 2 | 2012 | 41 | 0.080 |
Why?
|
| Histocompatibility Testing | 1 | 2009 | 2 | 0.080 |
Why?
|
| HLA-C Antigens | 1 | 2009 | 10 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2009 | 108 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 145 | 0.070 |
Why?
|
| Alemtuzumab | 1 | 2008 | 3 | 0.070 |
Why?
|
| Antilymphocyte Serum | 1 | 2008 | 3 | 0.070 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2008 | 7 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 1 | 2008 | 35 | 0.070 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2007 | 3 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 39 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2007 | 12 | 0.070 |
Why?
|
| Graft Survival | 1 | 2008 | 88 | 0.070 |
Why?
|
| Heart Transplantation | 1 | 2007 | 22 | 0.070 |
Why?
|
| Incidence | 2 | 2021 | 697 | 0.070 |
Why?
|
| Cytomegalovirus Infections | 1 | 2008 | 32 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 79 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 4509 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2007 | 108 | 0.070 |
Why?
|
| HLA-DP Antigens | 1 | 2006 | 1 | 0.060 |
Why?
|
| Complement C4b | 1 | 2006 | 1 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2018 | 421 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2006 | 71 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2021 | 1612 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 1026 | 0.060 |
Why?
|
| Religion and Medicine | 1 | 2004 | 25 | 0.060 |
Why?
|
| Anesthesia, Intravenous | 1 | 2024 | 5 | 0.050 |
Why?
|
| Anesthesia, General | 1 | 2024 | 23 | 0.050 |
Why?
|
| Hospitals, University | 2 | 2018 | 22 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2022 | 26 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 86 | 0.050 |
Why?
|
| Mice | 2 | 2021 | 1296 | 0.050 |
Why?
|
| Benzofurans | 1 | 2021 | 5 | 0.050 |
Why?
|
| Naphthoquinones | 1 | 2021 | 5 | 0.050 |
Why?
|
| Aniline Compounds | 1 | 2021 | 32 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2021 | 19 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2021 | 37 | 0.040 |
Why?
|
| Contrast Media | 1 | 2021 | 56 | 0.040 |
Why?
|
| Pancreas | 1 | 2021 | 29 | 0.040 |
Why?
|
| Cold Ischemia | 2 | 2011 | 3 | 0.040 |
Why?
|
| Kidney | 1 | 2021 | 139 | 0.040 |
Why?
|
| Mitotane | 1 | 2019 | 4 | 0.040 |
Why?
|
| United States | 2 | 2018 | 1873 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2020 | 118 | 0.040 |
Why?
|
| Argentina | 1 | 2019 | 1 | 0.040 |
Why?
|
| Blood Coagulation Disorders | 1 | 2019 | 12 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 278 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 52 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2019 | 23 | 0.040 |
Why?
|
| Digestive System Neoplasms | 1 | 2018 | 5 | 0.040 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2018 | 16 | 0.040 |
Why?
|
| Thymus Neoplasms | 1 | 2018 | 11 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2018 | 6 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 198 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 93 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2019 | 78 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 1042 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 13 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2017 | 41 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2017 | 31 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2019 | 322 | 0.030 |
Why?
|
| Edema | 1 | 2017 | 25 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2017 | 145 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 100 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 76 | 0.030 |
Why?
|
| Rabbits | 1 | 2017 | 178 | 0.030 |
Why?
|
| Sarcoma | 1 | 2017 | 71 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 728 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 183 | 0.030 |
Why?
|
| Italy | 1 | 2016 | 13 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 348 | 0.030 |
Why?
|
| Medical Audit | 1 | 2016 | 5 | 0.030 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 6 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 62 | 0.030 |
Why?
|
| Belgium | 1 | 2015 | 1 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 13 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 73 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 303 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 412 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 251 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 536 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 374 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2013 | 14 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 555 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2011 | 17 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2012 | 67 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 54 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 330 | 0.020 |
Why?
|
| Immunization | 1 | 2009 | 13 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2009 | 14 | 0.020 |
Why?
|
| Child | 1 | 2012 | 1131 | 0.020 |
Why?
|
| Histocompatibility | 1 | 2007 | 3 | 0.020 |
Why?
|
| Receptors, CXCR3 | 1 | 2007 | 4 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 18 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 259 | 0.020 |
Why?
|
| Wisconsin | 1 | 2006 | 3 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 2006 | 6 | 0.020 |
Why?
|
| Kidney Glomerulus | 1 | 2006 | 39 | 0.020 |
Why?
|
| Atrophy | 1 | 2006 | 81 | 0.020 |
Why?
|